1 / 22

Leah B. Herity, PharmD, MPH PGY1 Pharmacy Practice Resident

Evaluation of Antifungal Prophylaxis Strategy for Allogeneic Hematopoietic Cell Transplant Patients. Leah B. Herity, PharmD, MPH PGY1 Pharmacy Practice Resident Virginia Commonwealth University Health System. Disclosure.

alexscott
Télécharger la présentation

Leah B. Herity, PharmD, MPH PGY1 Pharmacy Practice Resident

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evaluation of Antifungal Prophylaxis Strategy for Allogeneic Hematopoietic Cell Transplant Patients • Leah B. Herity, PharmD, MPH • PGY1 Pharmacy Practice Resident • Virginia Commonwealth University Health System

  2. Disclosure • The authors and contributors of this project have no conflict of interest to disclose.

  3. Invasive Mold Infections (IMI)in Allogeneic Hematopoietic Cell Transplant (HCT) Patients Clin Chest Med. 2017 Dec;38(4):727-73 TransplInfect Dis. 2018;e12897 Biol Blood Marrow Transplant. 2013;19(8):11906

  4. Classification of IMI

  5. Previous Studies of Antifungal Prophylaxis RCT = randomized, controlled trial

  6. Primary Antifungal Prophylaxis Strategy at Virginia Commonwealth University (VCU) Health System • Patients may be switched to other antifungals depending on certain characteristics Post-engraftment Pre-engraftment

  7. Objective • To determine the incidence and outcomes of IMI in allogeneic HCT patients at VCU Health System receiving primary antifungal prophylaxis

  8. Methods • Retrospective medical record review • Data collected from Cerner Information Systems • January 1, 2013 through December 31, 2017 • Patients followed for 1 year post-transplant • Quality improvement project • VCU Institutional Review Board • Massey Cancer Center Protocol Review and Monitoring Committee (PRMC)

  9. Study Population

  10. Endpoints *Death within 12 weeks of IMI diagnosis

  11. Statistical Analysis • Demographics • Descriptive statistics • Primary outcome • Incidence rates • Kaplan-Meier survival estimates and log-rank tests • Secondary outcomes • Descriptive statistics • Chi-squared and Fisher’s Exact tests for risk factors • Analyses performed in Stata MP 15.1

  12. Patient Characteristics No statistically significant differences between groups

  13. Patient Characteristics *P<0.001 by chi-squared test

  14. Proven or Probable IMI Incidence Rate 33 cases per 100 patient-years

  15. Proven or Probable IMI Characteristics

  16. Proven or Probable IMI by Underlying Disease P-value = 0.44

  17. Proven or Probable IMI by Transplant Type P-value = 0.09

  18. Overall Survival P-value < 0.0001

  19. Limitations

  20. Conclusions

  21. Acknowledgments • May T. Aziz, PharmD, BCPS, BCOP • Teresa Potter, PharmD, MPH, BCPS • Oveimar A. De la Cruz, M.D.

  22. Questions? • Leah B. Herity, PharmD, MPH • leah.herity@vcuhealth.org • 804-828-6748

More Related